Efflux transporters in the blood–brain interfaces – in vitro and in vivo methods and correlations

Bibliography

• Schlageter KE, Molnar P, Lapin GD, Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28
   PubMed Web of Science ®Google Scholar
• Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res Dev Brain Res 1990;56:47-53
   PubMedGoogle Scholar
• Mae M, Armulik A, Betsholtz C. Getting to know the cast - cellular interactions and signaling at the neurovascular unit. Curr Pharm Des 2011;17:2750-4
   PubMedGoogle Scholar
• Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci 2011;14:1398-405
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002;1:131-9
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Kusuhara H, Lee YJ, Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res 2003;20:1394-400
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009;65:1063-70
   PubMed Web of Science ®Google Scholar
• Reichel V, Klas J, Fricker G, Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem 2010;115:200-8
   PubMed Web of Science ®Google Scholar
• Glavinas H, Mehn D, Jani M, Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol 2008;4:721-32
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001;299:620-8
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
   PubMed Web of Science ®Google Scholar
• von Richter O, Glavinas H, Krajcsi P, A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol 2009;379:11-26
   PubMedGoogle Scholar
• Sauna ZE, Nandigama K, Ambudkar SV. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J Biol Chem 2004;279:48855-64
   PubMedGoogle Scholar
• Deli MA, Abraham CS, Kataoka Y, Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005;25:59-127
   PubMed Web of Science ®Google Scholar
• Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990;429:47-62
   PubMed Web of Science ®Google Scholar
• Cucullo L, Hossain M, Rapp E, Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007;48:505-16
   PubMed Web of Science ®Google Scholar
• Cohen-Kashi Malina K, Cooper I, Teichberg VI. Closing the gap between the in-vivo and in-vitro blood-brain barrier tightness. Brain Res 2009;1284:12-21
   PubMedGoogle Scholar
• Thanabalasundaram G, Schneidewind J, Pieper C, The impact of pericytes on the blood-brain barrier integrity depends critically on the pericyte differentiation stage. Int J Biochem Cell Biol 2011;43:1284-93
   PubMed Web of Science ®Google Scholar
• Hughes HC. Swine in cardiovascular research. Lab Anim Sci 1986;36:348-50
   PubMedGoogle Scholar
• Veszelka S, Urbanyi Z, Pazmany T, Human serum amyloid P component attenuates the bacterial lipopolysaccharide-induced increase in blood-brain barrier permeability in mice. Neurosci Lett 2003;352:57-60
   PubMedGoogle Scholar
• Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev 2011;43:27-40
   PubMed Web of Science ®Google Scholar
• Patterson D, Graham C, Cherian C, A humanized mouse model for the reduced folate carrier. Mol Genet Metab 2008;93:95-103
   PubMedGoogle Scholar
• Weksler BB, Subileau EA, Perriere N, Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19:1872-4
   PubMed Web of Science ®Google Scholar
• Hatherell K, Couraud PO, Romero IA, Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods 2011;199:223-9
   PubMed Web of Science ®Google Scholar
• Tai LM, Reddy PS, Lopez-Ramirez MA, Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. Brain Res 2009;1292:14-24
   PubMedGoogle Scholar
• Cucullo L, Couraud PO, Weksler B, Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab 2008;28:312-28
   PubMed Web of Science ®Google Scholar
• Sano Y, Shimizu F, Abe M, Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 2010;225:519-28
   PubMed Web of Science ®Google Scholar
• Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol Neurobiol 2005;25:41-58
   PubMed Web of Science ®Google Scholar
• Lee HT, Chang YC, Tu YF, CREB activation mediates VEGF-A's protection of neurons and cerebral vascular endothelial cells. J Neurochem 2010;113:79-91
   PubMed Web of Science ®Google Scholar
• Hosoya K, Tetsuka K, Nagase K, Conditionally immortalized brain capillary endothelial cell lines established from a transgenic mouse harboring temperature-sensitive simian virus 40 large T-antigen gene. AAPS PharmSci 2000;2:E27
   PubMedGoogle Scholar
• Mukwaya G, MacGregor T, Hoelscher D, Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005;49:4903-10
   PubMed Web of Science ®Google Scholar
• Baehr C, Reichel V, Fricker G. Choroid plexus epithelial monolayers–a cell culture model from porcine brain. Cerebrospinal Fluid Res 2006;3:13
   PubMedGoogle Scholar
• Johanson CE, Stopa EG, McMillan PN. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol Biol 2011;686:101-31
   Google Scholar
• Shi LZ, Li GJ, Wang S, Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: tight junction proteins and transport properties. Toxicol In Vitro 2008;22:190-9
   PubMed Web of Science ®Google Scholar
• Szmydynger-Chodobska J, Pascale CL, Pfeffer AN, Expression of junctional proteins in choroid plexus epithelial cell lines: a comparative study. Cerebrospinal Fluid Res 2007;4:11
   PubMedGoogle Scholar
• Yousif S, Marie-Claire C, Roux F, Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 2007;1134:1-11
   Google Scholar
• Roberts LM, Black DS, Raman C, Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience 2008;155:423-38
   PubMed Web of Science ®Google Scholar
• Bachmeier CJ, Trickler WJ, Miller DW. Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab Dispos 2006;34:998-1003
   PubMed Web of Science ®Google Scholar
• Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 1996;277:1550-9
   PubMed Web of Science ®Google Scholar
• Camenzind RS, Chip S, Gutmann H, Preservation of transendothelial glucose transporter 1 and P-glycoprotein transporters in a cortical slice culture model of the blood-brain barrier. Neuroscience 2010;170:361-71
   PubMedGoogle Scholar
• Kovacs R, Raue C, Gabriel S, Functional test of multidrug transporter activity in hippocampal-neocortical brain slices from epileptic patients. J Neurosci Methods 2011;200:164-72
   PubMedGoogle Scholar
• Garberg P, Ball M, Borg N, In vitro models for the blood-brain barrier. Toxicol In Vitro 2005;19:299-334
   PubMed Web of Science ®Google Scholar
• Hakkarainen JJ, Jalkanen AJ, Kaariainen TM, Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm 2010;402:27-36
   PubMed Web of Science ®Google Scholar
• Lundquist S, Renftel M, Brillault J, Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res 2002;19:976-81
   PubMed Web of Science ®Google Scholar
• Glavinas H, von Richter O, Vojnits K, Calcein assay: a high-throughput method to assess P-gp inhibition. Xenobiotica 2011;41:712-19
   PubMed Web of Science ®Google Scholar
• Dash AK, Elmquist WF. Separation methods that are capable of revealing blood-brain barrier permeability. J Chromatogr B Analyt Technol Biomed Life Sci 2003;797:241-54
   PubMedGoogle Scholar
• Summerfield SG, Read K, Begley DJ, Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007;322:205-13
   PubMed Web of Science ®Google Scholar
• Akanuma S, Ohtsuki S, Doi Y, ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1-40) at the blood-brain barrier. Neurochem Int 2008;52:956-61
   PubMedGoogle Scholar
• Moriki Y, Suzuki T, Fukami T, Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method. Biol Pharm Bull 2004;27:932-5
   PubMed Web of Science ®Google Scholar
• Sakata A, Tamai I, Kawazu K, In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharmacol 1994;48:1989-92
   PubMed Web of Science ®Google Scholar
• Westerhout J, Danhof M, De Lange EC. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci 2011;100:3577-93
   PubMed Web of Science ®Google Scholar
• Sziraki I, Erdo F, Beery E, Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen 2011;16:886-94
   PubMedGoogle Scholar
• Tunblad K, Hammarlund-Udenaes M, Jonsson EN. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. Eur J Pharm Sci 2005;24:49-57
   PubMed Web of Science ®Google Scholar
• Xie R, Hammarlund-Udenaes M, de Boer AG, The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 1999;128:563-8
   PubMed Web of Science ®Google Scholar
• Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42:1231-40
   PubMed Web of Science ®Google Scholar
• Mensch J, Oyarzabal J, Mackie C, In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J Pharm Sci 2009;98:4429-68
   PubMed Web of Science ®Google Scholar
• Nicolazzo JA, Charman SA, Charman WN. Methods to assess drug permeability across the blood-brain barrier. J Pharm Pharmacol 2006;58:281-93
   PubMed Web of Science ®Google Scholar
• Polli JW, Jarrett JL, Studenberg SD, Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999;16:1206-12
   PubMed Web of Science ®Google Scholar
• Miller PW, Long NJ, Vilar R, Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl 2008;47:8998-9033
   PubMed Web of Science ®Google Scholar
• Shibata N, Matsnev A, Cahard D. Shelf-stable electrophilic trifluoromethylating reagents: a brief historical perspective. Beilstein J Org Chem 2010;6:65
   PubMedGoogle Scholar
• Kannan P, John C, Zoghbi SS, Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009;86:368-77
   PubMed Web of Science ®Google Scholar
• Eyal S, Ke B, Muzi M, Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 2010;87:579-85
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Humphreys JE, Webster LO, Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303:1029-37
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Wring SA, Shampine LJ, Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 2004;72:92-8
   PubMed Web of Science ®Google Scholar
• Josserand V, Pelerin H, de Bruin B, Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther 2006;316:79-86
   PubMed Web of Science ®Google Scholar
• Dehouck MP, Meresse S, Delorme P, An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem 1990;54:1798-801
   PubMed Web of Science ®Google Scholar
• Warren MS, Zerangue N, Woodford K, Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009;59:404-13
   PubMed Web of Science ®Google Scholar
• Cserr HF, Bundgaard M. Blood-brain interfaces in vertebrates: a comparative approach. Am J Physiol 1984;246:R277-88
   PubMed Web of Science ®Google Scholar
• Feng B, Mills JB, Davidson RE, In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008;36:268-75
   PubMed Web of Science ®Google Scholar
• Adachi Y, Suzuki H, Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 2001;18:1660-8
   PubMed Web of Science ®Google Scholar
• Ishiwata K, Kawamura K, Yanai K, In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 2007;48:81-7
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Granda BW, Grassi JM, Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos 2004;32:800-4
   PubMed Web of Science ®Google Scholar
• Miyama T, Takanaga H, Matsuo H, P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998;42:1738-44
   PubMed Web of Science ®Google Scholar
• Robey RW, Massey PR, Amiri-Kordestani L, ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem 2010;10:625-33
   PubMed Web of Science ®Google Scholar
• Shen J, Carcaboso AM, Hubbard KE, Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 2009;69:5885-92
   PubMed Web of Science ®Google Scholar
• Kodaira H, Kusuhara H, Fujita T, Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 2011;339:935-44
   PubMed Web of Science ®Google Scholar
• Tsaioun K, Bottlaender M, Mabondzo A. ADDME–Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC Neurol 2009;9(Suppl 1):S1
   PubMedGoogle Scholar
• Megard I, Garrigues A, Orlowski S, A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res 2002;927:153-67
   PubMed Web of Science ®Google Scholar
• Rajnai Z, Mehn D, Beery E, ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 2010;38:2000-6
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Katsukura Y, Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011;117:333-45
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yoshitomi S, Higuchi T, Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 2006;23:1460-72
   PubMed Web of Science ®Google Scholar
• Booth-Genthe CL, Louie SW, Carlini EJ, Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. J Pharmacol Toxicol Methods 2006;54:78-89
   PubMedGoogle Scholar
• Cecchelli R, Berezowski V, Lundquist S, Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650-61
   PubMed Web of Science ®Google Scholar
• Smith M, Omidi Y, Gumbleton M. Primary porcine brain microvascular endothelial cells: biochemical and functional characterisation as a model for drug transport and targeting. J Drug Target 2007;15:253-68
   PubMed Web of Science ®Google Scholar
• Omidi Y, Campbell L, Barar J, Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003;990:95-112
   PubMed Web of Science ®Google Scholar
• Tan KH, Dobbie MS, Felix RA, A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport 2001;12:1329-34
   PubMed Web of Science ®Google Scholar
• Wu YT, Kao YL, Lin LC, Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. Int J Pharm 2010;396:127-33
   PubMedGoogle Scholar
• Clinckers R, Smolders I, Michotte Y, Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. Br J Pharmacol 2008;155:1127-38
   PubMed Web of Science ®Google Scholar
• Okura T, Ozawa T, Ito Y, Enhancement by grapefruit juice of morphine antinociception. Biol Pharm Bull 2008;31:2338-41
   PubMed Web of Science ®Google Scholar
• Groenendaal D, Freijer J, de Mik D, Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br J Pharmacol 2007;151:701-12
   PubMed Web of Science ®Google Scholar
• Edwards JE, Brouwer KR, McNamara PJ. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother 2002;46:2284-6
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12:3557-60
   PubMed Web of Science ®Google Scholar
• Tsai TH. Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. Br J Pharmacol 2001;132:1310-16
   PubMed Web of Science ®Google Scholar
• Letrent SP, Pollack GM, Brouwer KR, Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 1999;27:827-34
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang H, Miller DW, Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 1995;211:719-26
   PubMed Web of Science ®Google Scholar
• Baltes S, Fedrowitz M, Tortos CL, Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007;320:331-43
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Tseng E, Nelson FR, Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos 2007;35:1341-9
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Fraga CH, Hubbard KE, Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 2006;66:11305-13
   PubMed Web of Science ®Google Scholar
• Elmeliegy MA, Carcaboso AM, Tagen M, Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011;17:89-99
   PubMed Web of Science ®Google Scholar
• Bernards CM. Cyclosporine-A-mediated inhibition of p-glycoprotein increases methylprednisolone entry into the central nervous system. Spinal Cord 2006;44:414-20
   PubMed Web of Science ®Google Scholar